The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Who will pay for this drug? This is more like a ransom than business: your money or your life. The federal government (taxpayers) have already paid for the R&D through foregone taxes. I suspect the feds have also helped pay for the research directly by subsidies. They usually do. Now governments are pressured to pay for them again while CEOs make tens of millions a year and the drug companies spend more on administration and marketing than they do on R&D. When will America wake up? People are fed up being ripped off again and again. Now it’s pay for this or die.

    • Well it sounds like GcMAF to me. The FDA raided the clinics, closed them down and have now approved the product, the price has gone from £20,000 to £360,000. Criminals, they should be brought to justice.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy